ClinicalTrials.gg
CompletedNCT02741791STRIDE-1Updated Mar 24, 2021

A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder

A Phase 3 interventional study of AXS-05 and Bupropion in Treatment Resistant Major Depressive Disorder, sponsored by Axsome Therapeutics, Inc.. Completed at 74 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-03-24.

Sponsored by Axsome Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
312
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Depressive Disorder, Major by Axsome Therapeutics, Inc. — 2 open to participants now, 2 under way, 1 of them phase 3. Depressive Disorder, Major · Axsome Therapeutics, Inc..

Enrollment
6th of 10
312 · median 320
Started
2016
the only one that year
Phase 3
5 of 10
1 open now
Registered
1st of 10
by date

Among the 10 studies in Depressive Disorder, Major by Axsome Therapeutics, Inc., this one is the 6th largest by enrollment, is the only one that started in 2016, is one of 5 in phase 3, and was the 1st registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

2 of the 10 studies in Depressive Disorder, Major by Axsome Therapeutics, Inc. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Depressive Disorder, Major by Axsome Therapeutics, Inc., or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of AXS-05 relative to bupropion in subjects with treatment resistant major depressive disorder (MDD).

This is a randomized, double-blind, active-controlled, 12-week, two-period study consisting of an open-label, bupropion lead-in period, and a double-blind treatment period. The trial is being conducted in subjects with treatment resistant MDD.

Subjects will be considered to have treatment resistant MDD if they have had a historical inadequate response to 1 or 2 antidepressant treatments and a prospective inadequate response to treatment with bupropion during the open-label, lead-in period.

03

Conditions studied

  • Treatment Resistant Major Depressive Disorder

Keywords

  • AXS-05
  • Major Depressive Disorder
  • Treatment Resistant Depression
  • TRD
  • MDD
  • Axsome
  • NMDA receptor
  • Refractory depression
  • Resistant depression
  • Depression
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Currently meets criteria for MDD
  • History of inadequate response to 1 or 2 adequate antidepressant treatments
  • (BMI) between 18 and 40 kg/m2, inclusive
  • Agree to use adequate method of for the duration of the study
  • Additional criteria may apply

Key Exclusion Criteria:

  • Suicide risk
  • Treatment with any drug within 6 months
  • History of electroconvulsive therapy (ECT), vagus nerve stimulation, transcranial magnetic stimulation, or any experimental central nervous system treatment during the current episode or in the past 6 months
  • Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study
  • Additional criteria may apply
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
312 participants (actual)

Study arms

  • Experimental
    AXS-05

    Drug: AXS-05

  • Active comparator
    Bupropion

    Drug: Bupropion

Interventions

  • DrugAXS-05

    AXS-05 taken daily for 6 weeks.

  • Buproprion taken daily for 6 weeks.

06

What researchers measure

Primary outcomes

  1. Montgomery-Åsberg Depression Rating Scale (MADRS) total score

    The MADRS is used to assess depressive symptomatology during the previous week. Subjects are rated on 10 items to assess feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating and lack of interest. Each item is scored on a 7-point scale. A score of 0 indicates the absence of symptoms, and a score of 6 indicates symptoms of maximum severity.

    Time frame: MADRS change from Baseline to End of Study (6 weeks)

Secondary outcomes

  1. Clinical Global Impressions-Severity (CGI-S)

    Time frame: Baseline to End of Study (6 weeks)

  2. Hamilton Depression Rating Scale - 17 items (HAMD-17)

    Time frame: Baseline to End of Study (6 weeks)

07

Study locations

74 sites
  • Phoenix, Arizona, United States
  • Little Rock, Arkansas, United States
  • Anaheim, California, United States
  • Beverly Hills, California, United States
  • Garden Grove, California, United States
  • Oakland, California, United States
  • Oceanside, California, United States
  • Panorama City, California, United States
  • Redlands, California, United States
  • Riverside, California, United States
  • San Diego, California, United States
  • San Francisco, California, United States
  • Sherman Oaks, California, United States
  • Temecula, California, United States
  • Upland, California, United States
  • Colorado Springs, Colorado, United States
  • Cromwell, Connecticut, United States
  • Washington, District of Columbia 20016, United States
  • Coral Springs, Florida, United States
  • Fort Lauderdale, Florida, United States
  • Fort Myers, Florida, United States
  • Gainesville, Florida, United States
  • Jacksonville, Florida 32256, United States
  • Lakeland, Florida, United States
  • North Miami, Florida, United States
  • Orlando, Florida, United States
  • Pensacola, Florida, United States
  • Saint Petersburg, Florida, United States
  • Atlanta, Georgia 30328, United States
  • Boise, Idaho, United States
  • Skokie, Illinois, United States
  • Shreveport, Louisiana, United States
  • Baltimore, Maryland, United States
  • Saint Charles, Missouri, United States
  • Saint Louis, Missouri, United States
  • Lincoln, Nebraska, United States
  • Las Vegas, Nevada, United States
  • Nashua, New Hampshire, United States
  • Berlin, New Jersey, United States
  • Cherry Hill, New Jersey, United States
  • Marlton, New Jersey, United States
  • Princeton, New Jersey, United States
  • Toms River, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • Brooklyn, New York, United States
  • Jamaica, New York 11432, United States
  • New York, New York, United States
  • Rochester, New York, United States
  • Staten Island, New York, United States
  • Charlotte, North Carolina, United States
  • Canton, Ohio, United States
  • Dayton, Ohio, United States
  • Middleburg Heights, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Portland, Oregon, United States
  • Salem, Oregon, United States
  • Allentown, Pennsylvania, United States
  • Media, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Lincoln, Rhode Island, United States
  • Charleston, South Carolina, United States
  • Memphis, Tennessee 38119, United States
  • Austin, Texas, United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Wichita Falls, Texas, United States
  • Orem, Utah, United States
  • Charlottesville, Virginia, United States
  • Herndon, Virginia, United States
  • Bellevue, Washington, United States
  • Seattle, Washington, United States
  • Spokane, Washington, United States
  • Waukesha, Wisconsin, United States
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2016, a primary completion of Mar 2020 and a completion of Mar 2020. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2016
First posted
Apr 18, 2016
Start
Mar 2016
Primary completionActual
Mar 20, 2020
CompletionActual
Mar 20, 2020
Results delay requested
Mar 19, 2021
Last update
Mar 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02741791
Responsible party
Sponsor
First posted
Apr 18, 2016
Start date
Mar 2016
Primary completion
Mar 20, 2020
Completion
Mar 20, 2020
Last update
Mar 24, 2021

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dextromethorphan/Bupropion Tablet AXS-05

Start the discussion